Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Kawaratani H, Tsujimoto T, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Oncol Lett. 2011 Jan;2(1):69-73. doi: 10.3892/ol.2010.196. Epub 2010 Oct 5. Oncol Lett. 2011. PMID: 22870131 Free PMC article.
Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Oncol Rep. 2011 Dec;26(6):1547-53. doi: 10.3892/or.2011.1433. Epub 2011 Aug 24. Oncol Rep. 2011. PMID: 21874260 Clinical Trial.
Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance.
Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Oncol Rep. 2013 Aug;30(2):545-52. doi: 10.3892/or.2013.2497. Epub 2013 May 27. Oncol Rep. 2013. PMID: 23708326 Free PMC article. Clinical Trial.
Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C.
Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H. Yoshiji H, et al. Among authors: toyohara m. World J Gastroenterol. 2006 Nov 14;12(42):6786-91. doi: 10.3748/wjg.v12.i42.6786. World J Gastroenterol. 2006. PMID: 17106926 Free PMC article. Clinical Trial.
Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis.
Yoshiji H, Noguchi R, Yamazaki M, Ikenaka Y, Sawai M, Ishikawa M, Kawaratani H, Mashitani T, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. World J Gastroenterol. 2007 Jun 21;13(23):3259-61. doi: 10.3748/wjg.v13.i23.3259. World J Gastroenterol. 2007. PMID: 17589909 Free PMC article.
Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report.
Mashitani T, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, Kawaratani H, Matsuo N, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Sawai M, Morioka C, Tsujimoto T, Kitade M, Kaji K, Aihara Y, Fukui H. Mashitani T, et al. Among authors: toyohara m. Cases J. 2009 Jan 7;2(1):18. doi: 10.1186/1757-1626-2-18. Cases J. 2009. PMID: 19128460 Free PMC article.
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. J Hepatol. 2009 Aug;51(2):315-21. doi: 10.1016/j.jhep.2009.04.011. Epub 2009 May 15. J Hepatol. 2009. PMID: 19501932 Clinical Trial.
Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.
Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H. Kitade M, et al. Among authors: toyohara m. World J Gastroenterol. 2009 Nov 7;15(41):5193-9. doi: 10.3748/wjg.15.5193. World J Gastroenterol. 2009. PMID: 19891019 Free PMC article.
Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report.
Shirai Y, Yoshiji H, Ko S, Yamazaki M, Ikenaka Y, Noguchi R, Morioka C, Kaji K, Aihara Y, Nakanishi K, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Uemura M, Nakajima Y, Fukui H. Shirai Y, et al. Among authors: toyohara m. J Med Case Rep. 2011 Mar 29;5:124. doi: 10.1186/1752-1947-5-124. J Med Case Rep. 2011. PMID: 21447168 Free PMC article.
Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Douhara A, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Mol Med Rep. 2012 Feb;5(2):539-44. doi: 10.3892/mmr.2011.676. Epub 2011 Nov 15. Mol Med Rep. 2012. PMID: 22089860 Clinical Trial.
81 results